MISTRAL project deciphering microbiome role on HIV pathogenesis & cure

The EU-funded MISTRAL project is exploring the gut microbiota in relation to HIV-1, seeking microbiome biomarkers to support development of interventions that mitigate infection and enhance response to vaccines and therapies.

The EU-funded MISTRAL project is exploring the gut microbiota in relation to HIV-1, seeking microbiome biomarkers to support development of interventions that mitigate infection and enhance response to vaccines and therapies.
June 11, 2021

✹The EU-funded MISTRAL project is exploring the gut microbiota in relation to HIV-1, seeking microbiome biomarkers to support development of interventions that mitigate infection and enhance response to vaccines and therapies. In addition, the creation of a publicly accessible database will aid inpatient screening and stratification. A cloud-based tool will also facilitate microbiome interpretation for reseach and clinical purposes.

✹Although the microbiome has been the subject of intense research over recent decades, very few publications have addressed its potential role in HIV/AIDS – and most of these have focused on the genital microbiome. Increasing evidence supports a role for the gut microbiome in immune system disorders, chronic inflammation and accelerated ageing, all hallmarks of HIV-1 infection.

✹ASPHALION is proud Regulatory partner of this EU granted project. Our experts, Christopher Mann and Laura Mendieta took part on the consortium meeting yesterday, where a project follow-up and and update on all working packages was successfully carried out.  

✹Also, we are more than happy to share the news with you about the launch of the project´s website:

https://www.mistral-hiv.eu/#first

✹For further information, you can contact us at: [email protected]

 

 

Search News & Events

  • Filter by category

Share

Related news and events

HORIZON EUROPE | NABIHEAL progress meeting

Two years into the NABIHEAL project, Asphalion experts Marta Rayo Lunar and Sergio Veiga attended the consortium meeting in Zagreb, hosted by IMI, to review

HORIZON EUROPE PROJECT | KeratOPrinter Kick-Off Meeting

Corneal blindness affects over 11.7 million people worldwide, yet only 1 in 70 patients receive a corneal transplant due to a severe donor shortage. The KeratOPrinter project aims to address this gap by developing a groundbreaking 4D bioprinting suite capable of producing fully functional, biocompatible human corneas. Combining expertise from world-class partners, the project focuses on scalable cell sources, advanced bioinks, high-precision bioprinting, clinical handling solutions, regulatory compliance, and a strong collaborative network. By 2035, KeratOPrinter seeks to revolutionize corneal transplantation and restore vision for millions.

ARDAT PROJECT

A new year, new classes, and a deep dive into advanced therapies, including discussions on the ARDAT project, as part of the University of Sheffield’s

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting